Use of CGM can optimize glycemic control; however, consistency of CGM use in youth and teens/young adults with T1D has been low in prior studies. We assessed 1-year use of Dexcom CGM in young children (ages 2 to <8y) in the Strategies to Enhance New CGM in Early Childhood (SENCE) study and in teens/young adults (ages 14 to <25y) in the CGM Intervention in Teens and Young Adults (CITY) study. Analyses included average # of days/week and percent of CGM wear time over 4 weeks prior to 6 and 12-month study visits. CGM use data from month 6 and 12 months are shown in the Table. For 84 youth in SENCE, median # days/week of CGM use was 7.0 with CGM being used 92% of time at 12 months; 79% were using CGM 7 days/week and only 2% discontinued CGM altogether. In 70 teens/young adults in CITY, median # of days/week of CGM use was 6.8, with CGM being used 86% of time at 12 months; 46% were using CGM 7 days/week and 9% discontinued CGM. At 12 months 88% of SENCE participants and 97% of CITY participants using CGM reported dosing insulin with CGM without using confirmatory fingerstick blood glucose value; 54% and 55%, respectively used remote monitoring features. CGM use in cohorts of very young children, teens and young adults was higher than previously reported. Improved CGM features, including mobile app data display, remote monitoring and non-adjunctive approval for dosing insulin, likely contributed to increased use.
D. DeSalvo: Consultant; Self; Dexcom, Inc., Insulet Corporation. L. Kanapka: None. C. Bauza: None. C. Xie: None. L. DiMeglio: None. L.M. Laffel: Advisory Panel; Self; Roche Diabetes Care. Consultant; Self; Boehringer Ingelheim Pharmaceuticals, Inc., ConvaTec Inc., Dexcom, Inc., Insulet Corporation, Insulogic LLC, Janssen Pharmaceuticals, Inc., Lilly Diabetes, Novo Nordisk Inc., Sanofi US. K. Miller: None.
The Leona M. and Harry B. Helmsley Charitable Trust; Dexcom, Inc.